Details of the Drug

General Information of Drug (ID: DM5WFNP)

Drug Name
Abarelix
Synonyms
Plenaxis; Abarelix [USAN]; Plenaxis depot; PPI 149; R 3827; PPI-149; Plenaxis (TN); R-3827; Abarelix (USAN/INN); Abarelix-Depot-M; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-10
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 1416.1
Topological Polar Surface Area (xlogp) 3.7
Rotatable Bond Count (rotbonds) 38
Hydrogen Bond Donor Count (hbonddonor) 13
Hydrogen Bond Acceptor Count (hbondacc) 16
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 13.2 +/- 3.2 days [3]
Metabolism
The drug is metabolized via the hydrolysis of peptide bonds [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03363 micromolar/kg/day [5]
Chemical Identifiers
Formula
C72H95ClN14O14
IUPAC Name
(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
Canonical SMILES
C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
InChI
InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
InChIKey
AIWRTTMUVOZGPW-HSPKUQOVSA-N
Cross-matching ID
PubChem CID
16131215
ChEBI ID
CHEBI:337298
CAS Number
183552-38-7
DrugBank ID
DB00106
TTD ID
D01AHO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gonadotropin-releasing hormone receptor (GNRHR) TT8R70G GNRHR_HUMAN Modulator [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Abarelix (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Abarelix and Ivosidenib. Acute myeloid leukaemia [2A60] [17]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Abarelix and Midostaurin. Acute myeloid leukaemia [2A60] [18]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Abarelix and Idarubicin. Acute myeloid leukaemia [2A60] [18]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Abarelix and Daunorubicin. Acute myeloid leukaemia [2A60] [18]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Gilteritinib. Acute myeloid leukaemia [2A60] [18]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Abarelix and Oliceridine. Acute pain [MG31] [18]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Galantamine. Alzheimer disease [8A20] [19]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Rivastigmine. Alzheimer disease [8A20] [19]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Donepezil. Alzheimer disease [8A20] [19]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Abarelix and Metronidazole. Amoebiasis [1A36] [20]
Ranolazine DM0C9IL Moderate Increased risk of prolong QT interval by the combination of Abarelix and Ranolazine. Angina pectoris [BA40] [18]
Ivabradine DM0L594 Major Increased risk of prolong QT interval by the combination of Abarelix and Ivabradine. Angina pectoris [BA40] [18]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Abarelix and Dronedarone. Angina pectoris [BA40] [19]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Abarelix and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [21]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [18]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Abarelix and Cilostazol. Arterial occlusive disease [BD40] [18]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Abarelix and Voriconazole. Aspergillosis [1F20] [18]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Abarelix and Posaconazole. Aspergillosis [1F20] [18]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Levalbuterol. Asthma [CA23] [22]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Terbutaline. Asthma [CA23] [23]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Pirbuterol. Asthma [CA23] [22]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Salbutamol. Asthma [CA23] [22]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Abarelix and Formoterol. Asthma [CA23] [23]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Abarelix and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [18]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [18]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Abarelix and Desipramine. Attention deficit hyperactivity disorder [6A05] [18]
Oxytocin DMDL27I Moderate Increased risk of prolong QT interval by the combination of Abarelix and Oxytocin. Autism spectrum disorder [6A02] [18]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Ofloxacin. Bacterial infection [1A00-1C4Z] [18]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [18]
Erythromycin DM4K7GQ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Erythromycin. Bacterial infection [1A00-1C4Z] [18]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Abarelix and Clarithromycin. Bacterial infection [1A00-1C4Z] [18]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Abarelix and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [19]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Abarelix and Gemifloxacin. Bacterial infection [1A00-1C4Z] [18]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Norfloxacin. Bacterial infection [1A00-1C4Z] [18]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Abarelix and Levofloxacin. Bacterial infection [1A00-1C4Z] [18]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Abarelix and Moxifloxacin. Bacterial infection [1A00-1C4Z] [24]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Abarelix and Telithromycin. Bacterial infection [1A00-1C4Z] [18]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Abarelix and Retigabine. Behcet disease [4A62] [18]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Loperamide. Bowel habit change [ME05] [25]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Abarelix and Eribulin. Breast cancer [2C60-2C6Y] [18]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Abarelix and Lapatinib. Breast cancer [2C60-2C6Y] [18]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Tamoxifen. Breast cancer [2C60-2C6Y] [18]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Abarelix and Toremifene. Breast cancer [2C60-2C6Y] [19]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Abarelix and Bosutinib. Breast cancer [2C60-2C6Y] [18]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Abarelix and Sotalol. Cardiac arrhythmia [BC9Z] [19]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Abarelix and Dofetilide. Cardiac arrhythmia [BC9Z] [19]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Abarelix and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [18]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Olodaterol. Chronic obstructive pulmonary disease [CA22] [23]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Vilanterol. Chronic obstructive pulmonary disease [CA22] [22]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Salmeterol. Chronic obstructive pulmonary disease [CA22] [23]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Indacaterol. Chronic obstructive pulmonary disease [CA22] [23]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Arformoterol. Chronic obstructive pulmonary disease [CA22] [23]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Abarelix and Oxaliplatin. Colorectal cancer [2B91] [18]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Isoproterenol. Conduction disorder [BC63] [22]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Halothane. Corneal disease [9A76-9A78] [18]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Abarelix and Propofol. Corneal disease [9A76-9A78] [26]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Sevoflurane. Corneal disease [9A76-9A78] [18]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Abarelix and Methadone. Cough [MD12] [19]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Abarelix and Clofazimine. Crohn disease [DD70] [18]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Abarelix and Mifepristone. Cushing syndrome [5A70] [19]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Abarelix and Pasireotide. Cushing syndrome [5A70] [19]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Abarelix and Osilodrostat. Cushing syndrome [5A70] [18]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Abarelix and Sertraline. Depression [6A70-6A7Z] [18]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Abarelix and Trimipramine. Depression [6A70-6A7Z] [18]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Imipramine. Depression [6A70-6A7Z] [18]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Abarelix and Fluoxetine. Depression [6A70-6A7Z] [18]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Abarelix and Escitalopram. Depression [6A70-6A7Z] [19]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Trazodone. Depression [6A70-6A7Z] [18]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Abarelix and Amitriptyline. Depression [6A70-6A7Z] [18]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Abarelix and Amoxapine. Depression [6A70-6A7Z] [18]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Mirtazapine. Depression [6A70-6A7Z] [18]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Abarelix and Protriptyline. Depression [6A70-6A7Z] [18]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Abarelix and Doxepin. Depression [6A70-6A7Z] [18]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Abarelix and Maprotiline. Depression [6A70-6A7Z] [18]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Venlafaxine. Depression [6A70-6A7Z] [18]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Abarelix and Citalopram derivative 1. Discovery agent [N.A.] [19]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Abarelix and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [18]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Abarelix and Deutetrabenazine. Dystonic disorder [8A02] [18]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Abarelix and Ingrezza. Dystonic disorder [8A02] [18]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Abarelix and Solifenacin. Functional bladder disorder [GC50] [18]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Abarelix and Pentamidine. Fungal infection [1F29-1F2F] [18]
Fluconazole DMOWZ6B Moderate Increased risk of prolong QT interval by the combination of Abarelix and Fluconazole. Fungal infection [1F29-1F2F] [18]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Abarelix and Ketoconazole. Fungal infection [1F29-1F2F] [18]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Abarelix and Sunitinib. Gastrointestinal stromal tumour [2B5B] [18]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Abarelix and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [18]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Abarelix and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [27]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Abarelix and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [28]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [18]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Abarelix and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [18]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Polyethylene glycol. Irritable bowel syndrome [DD91] [18]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Abarelix and Crizotinib. Lung cancer [2C25] [29]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Abarelix and Ceritinib. Lung cancer [2C25] [19]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Abarelix and Osimertinib. Lung cancer [2C25] [30]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Abarelix and Selpercatinib. Lung cancer [2C25] [31]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Abarelix and Lumefantrine. Malaria [1F40-1F45] [20]
Chloroquine DMSI5CB Moderate Increased risk of prolong QT interval by the combination of Abarelix and Chloroquine. Malaria [1F40-1F45] [18]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Abarelix and Hydroxychloroquine. Malaria [1F40-1F45] [18]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Quinine. Malaria [1F40-1F45] [18]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Abarelix and Primaquine. Malaria [1F40-1F45] [18]
Mefloquine DMWT905 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Mefloquine. Malaria [1F40-1F45] [18]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [18]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Abarelix and Arsenic trioxide. Mature B-cell lymphoma [2A85] [32]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Abarelix and Vemurafenib. Melanoma [2C30] [19]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Abarelix and LGX818. Melanoma [2C30] [18]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Abarelix and Panobinostat. Multiple myeloma [2A83] [33]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Thalidomide. Multiple myeloma [2A83] [20]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Abarelix and Siponimod. Multiple sclerosis [8A40] [20]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Abarelix and Fingolimod. Multiple sclerosis [8A40] [19]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Abarelix and Ozanimod. Multiple sclerosis [8A40] [34]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Abarelix and Romidepsin. Mycosis fungoides [2B01] [18]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Abarelix and Nilotinib. Myeloproliferative neoplasm [2A20] [19]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Abarelix and Dasatinib. Myeloproliferative neoplasm [2A20] [18]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Abarelix and Droperidol. Nausea/vomiting [MD90] [19]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Abarelix and Prochlorperazine. Nausea/vomiting [MD90] [18]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Abarelix and Promethazine. Nausea/vomiting [MD90] [18]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Abarelix and Palonosetron. Nausea/vomiting [MD90] [18]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Granisetron. Nausea/vomiting [MD90] [18]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Abarelix and Dolasetron. Nausea/vomiting [MD90] [19]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Abarelix and Ondansetron. Nausea/vomiting [MD90] [18]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Abarelix and Entrectinib. Non-small cell lung cancer [2C25] [18]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Lofexidine. Opioid use disorder [6C43] [18]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Rucaparib. Ovarian cancer [2C73] [18]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Abarelix and Dextropropoxyphene. Pain [MG30-MG3Z] [18]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Abarelix and Buprenorphine. Pain [MG30-MG3Z] [18]
Tramadol DMRQD04 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Tramadol. Pain [MG30-MG3Z] [18]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Abarelix and Triclabendazole. Parasitic worm infestation [1F90] [18]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Abarelix and Pimavanserin. Parkinsonism [8A00] [18]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Apomorphine. Parkinsonism [8A00] [18]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Abarelix and Famotidine. Peptic ulcer [DA61] [20]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Abarelix and Macimorelin. Pituitary gland disorder [5A60-5A61] [35]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Abarelix and Lefamulin. Pneumonia [CA40] [17]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Abarelix and Alfuzosin. Prostate hyperplasia [GA90] [18]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Abarelix and Fluphenazine. Psychotic disorder [6A20-6A25] [18]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Abarelix and Sorafenib. Renal cell carcinoma [2C90] [18]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Abarelix and Gatifloxacin. Respiratory infection [CA07-CA4Z] [24]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Abarelix and Quetiapine. Schizophrenia [6A20] [18]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Abarelix and Mesoridazine. Schizophrenia [6A20] [20]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Abarelix and Thioridazine. Schizophrenia [6A20] [18]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Abarelix and Aripiprazole. Schizophrenia [6A20] [20]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Abarelix and Iloperidone. Schizophrenia [6A20] [19]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Abarelix and Paliperidone. Schizophrenia [6A20] [18]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Abarelix and Haloperidol. Schizophrenia [6A20] [19]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Abarelix and Perphenazine. Schizophrenia [6A20] [18]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Chlorpromazine. Schizophrenia [6A20] [18]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Abarelix and Clozapine. Schizophrenia [6A20] [19]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Abarelix and Trifluoperazine. Schizophrenia [6A20] [18]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Abarelix and Ziprasidone. Schizophrenia [6A20] [19]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Abarelix and Risperidone. Schizophrenia [6A20] [18]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Abarelix and Olanzapine. Schizophrenia [6A20] [20]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Abarelix and Amisulpride. Schizophrenia [6A20] [36]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Asenapine. Schizophrenia [6A20] [18]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Abarelix and Pimozide. Schizophrenia [6A20] [18]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Vardenafil. Sexual dysfunction [HA00-HA01] [18]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Abarelix and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [18]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Abarelix and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [19]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Abarelix and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [18]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Pitolisant. Somnolence [MG42] [18]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Abarelix and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [18]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Abarelix and Ibutilide. Supraventricular tachyarrhythmia [BC81] [19]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Abarelix and Adenosine. Supraventricular tachyarrhythmia [BC81] [19]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Abarelix and Zithromax. Syphilis [1A61-1A6Z] [18]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Abarelix and Anagrelide. Thrombocytosis [3B63] [19]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Lenvatinib. Thyroid cancer [2D10] [18]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Abarelix and Cabozantinib. Thyroid cancer [2D10] [18]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Abarelix and Papaverine. Tonus and reflex abnormality [MB47] [37]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Abarelix and Tizanidine. Tonus and reflex abnormality [MB47] [18]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Abarelix and Tacrolimus. Transplant rejection [NE84] [18]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Abarelix and Disopyramide. Ventricular tachyarrhythmia [BC71] [19]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Abarelix and Procainamide. Ventricular tachyarrhythmia [BC71] [19]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Abarelix and Propafenone. Ventricular tachyarrhythmia [BC71] [18]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Abarelix and Flecainide. Ventricular tachyarrhythmia [BC71] [18]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Abarelix and Amiodarone. Ventricular tachyarrhythmia [BC71] [19]
⏷ Show the Full List of 172 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1188).
2 Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2(6):677-96.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
10 Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
11 Clinical pipeline report, company report or official report of Takeda (2009).
12 Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
13 Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
14 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
15 Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.
16 Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34.
17 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Canadian Pharmacists Association.
20 Cerner Multum, Inc. "Australian Product Information.".
21 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
23 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
25 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
26 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
27 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
28 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
29 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
30 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
31 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
32 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
33 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
34 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
35 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
36 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
37 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]